130 related articles for article (PubMed ID: 32779428)
21. Pharmacokinetics and pharmacodynamics of liposomal mifamurtide in adult volunteers with mild or moderate renal impairment.
Venkatakrishnan K; Liu Y; Noe D; Mertz J; Bargfrede M; Marbury T; Farbakhsh K; Oliva C; Milton A
Br J Clin Pharmacol; 2014 Jun; 77(6):986-97. PubMed ID: 24134181
[TBL] [Abstract][Full Text] [Related]
22. Liposomal muramyl tripeptide phosphatidylethanolamine: Targeting and activating macrophages for adjuvant treatment of osteosarcoma.
Nardin A; Lefebvre ML; Labroquère K; Faure O; Abastado JP
Curr Cancer Drug Targets; 2006 Mar; 6(2):123-33. PubMed ID: 16529542
[TBL] [Abstract][Full Text] [Related]
23. Biologic therapy for osteosarcoma using liposome-encapsulated muramyl tripeptide.
Kleinerman ES
Hematol Oncol Clin North Am; 1995 Aug; 9(4):927-38. PubMed ID: 7490249
[TBL] [Abstract][Full Text] [Related]
24. Efficacy of liposomal muramyl tripeptide (CGP 19835A) in the treatment of relapsed osteosarcoma.
Kleinerman ES; Gano JB; Johnston DA; Benjamin RS; Jaffe N
Am J Clin Oncol; 1995 Apr; 18(2):93-9. PubMed ID: 7900714
[TBL] [Abstract][Full Text] [Related]
25. Liposome-encapsulated muramyl tripeptide: a new biologic response modifier for the treatment of osteosarcoma.
Kleinerman ES; Maeda M; Jaffe N
Cancer Treat Res; 1993; 62():101-7. PubMed ID: 8096724
[TBL] [Abstract][Full Text] [Related]
26. Liposomal muramyl tripeptide phosphatidyl ethanolamine: a safe and effective agent against osteosarcoma pulmonary metastases.
Mori K; Ando K; Heymann D
Expert Rev Anticancer Ther; 2008 Feb; 8(2):151-9. PubMed ID: 18279055
[TBL] [Abstract][Full Text] [Related]
27. Ergotamine-induced pleural and pericardial effusion successfully treated with colchicine.
Helsen V; Decoutere L; Spriet I; Fagard K; Boonen S; Tournoy J
Acta Clin Belg; 2013; 68(2):113-5. PubMed ID: 23967719
[TBL] [Abstract][Full Text] [Related]
28. Muramyl Tripeptide-Phosphatidyl Ethanolamine Encapsulated in Liposomes (L-MTP-PE) in the Treatment of Osteosarcoma.
Meyers PA
Adv Exp Med Biol; 2020; 1257():133-139. PubMed ID: 32483736
[TBL] [Abstract][Full Text] [Related]
29. Liposomal muramyl tripeptide phosphatidyl ethanolamine: ifosfamide-containing chemotherapy in osteosarcoma.
Anderson P
Future Oncol; 2006 Jun; 2(3):333-43. PubMed ID: 16787112
[TBL] [Abstract][Full Text] [Related]
30. A case of Meigs' syndrome with preceding pericardial effusion in advance of pleural effusion.
Okuda K; Noguchi S; Narumoto O; Ikemura M; Yamauchi Y; Tanaka G; Takai D; Fukayama M; Nagase T
BMC Pulm Med; 2016 May; 16(1):71. PubMed ID: 27160723
[TBL] [Abstract][Full Text] [Related]
31. Prospectively planned analysis of data from a phase III study of liposomal muramyltripeptide phosphatidylethanolamine in the treatment of osteosarcoma.
Romet-Lemonne JL; Mills B; Fridman WH; Munsell M
J Clin Oncol; 2005 Sep; 23(26):6437-8. PubMed ID: 16155031
[No Abstract] [Full Text] [Related]
32. Influence of chemotherapy administration on monocyte activation by liposomal muramyl tripeptide phosphatidylethanolamine in children with osteosarcoma.
Kleinerman ES; Snyder JS; Jaffe N
J Clin Oncol; 1991 Feb; 9(2):259-67. PubMed ID: 1988574
[TBL] [Abstract][Full Text] [Related]
33. Liposomal MTP-PE for the adjuvant therapy of osteosarcoma.
Kleinerman ES; Jaffe N
Prog Clin Biol Res; 1990; 343():263-79. PubMed ID: 2198583
[No Abstract] [Full Text] [Related]
34. Mifamurtide and TAM-like macrophages: effect on proliferation, migration and differentiation of osteosarcoma cells.
Punzo F; Bellini G; Tortora C; Pinto DD; Argenziano M; Pota E; Paola AD; Martino MD; Rossi F
Oncotarget; 2020 Feb; 11(7):687-698. PubMed ID: 32133045
[TBL] [Abstract][Full Text] [Related]
35. [A case of osteosarcoma of the rib with bloody pleural effusion].
Nakamura A; Yamada Y; Yamamoto T; Yamamoto K; Takeuchi T
Nihon Kyobu Shikkan Gakkai Zasshi; 1993 Mar; 31(3):394-8. PubMed ID: 8315912
[TBL] [Abstract][Full Text] [Related]
36. [L-MTP-PE--a potential antineoplastic agent].
Dzierzbicka K; Gozdowska M; Kołodziejczyk AM
Postepy Hig Med Dosw; 1997; 51(2):227-36. PubMed ID: 9235567
[TBL] [Abstract][Full Text] [Related]
37. Review of mifamurtide in the treatment of patients with osteosarcoma.
Kager L; Pötschger U; Bielack S
Ther Clin Risk Manag; 2010 Jun; 6():279-86. PubMed ID: 20596505
[TBL] [Abstract][Full Text] [Related]
38. In vitro and in vivo enhancement of canine pulmonary alveolar macrophage cytotoxic activity against canine osteosarcoma cells.
Kurzman ID; Shi F; Vail DM; MacEwen EG
Cancer Biother Radiopharm; 1999 Apr; 14(2):121-8. PubMed ID: 10850295
[TBL] [Abstract][Full Text] [Related]
39. Improved osteosarcoma survival with addition of mifamurtide to conventional chemotherapy - Observational prospective single institution analysis.
Múdry P; Kýr M; Rohleder O; Mahdal M; Staniczková Zambo I; Ježová M; Tomáš T; Štěrba J
J Bone Oncol; 2021 Jun; 28():100362. PubMed ID: 33948428
[TBL] [Abstract][Full Text] [Related]
40. Synthesis of isotopically labeled versions of L-MTP-PE (mifamurtide) and MDP.
Li Y; Plesescu M; Prakash SR
J Labelled Comp Radiopharm; 2013; 56(9-10):475-9. PubMed ID: 24285524
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
